The Section on Clinical Genomics and Experimental Therapeutics (CGET) at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), one of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS), is recruiting for post-doctoral fellows (MD and/or PhD) to conduct research in the laboratory located in the Mark O Hatfield Clinical Research Center on the main NIH campus in Bethesda, MD.
The section uses translational research strategies to investigate genetic susceptibility and neuroadaptive processes underlying the development and treatment of alcohol dependence, addiction and related phenotypes. Specifically, the lab focuses on molecular mechanisms involved in addiction biology. Candidates should have a strong background in molecular biology, molecular genetics and epigenetics, sequencing techniques and bioinformatics analyses, as well as a history of solid prior publications.
Strong verbal and written communication skills are essential. Candidates must have less than 5 years of post-doctoral training. Salary will be set commensurate with experience and accomplishments. Interested candidates should apply by submitting a current C.V. and bibliography, a brief statement of research accomplishments and interests, along with 3 reference contacts. Applications can be submitted electronically or by mail to:
Falk W. Lohoff, MD
Chief, Section on Clinical Genomics and Experimental Therapeutics (CGET)
National Institute of Alcohol Abuse and Alcoholism
The National Institutes of Health are dedicated to building a diverse community in its training and employment programs. Women, minorities and persons with disabilities are strongly encouraged to apply.
Additional Salary Information: Salary will be set commensurate with experience and accomplishments.
Internal Number: CGET2019
About Falk Lohoff, M.D. NIAAA CGET
The Section on Clinical Genomics and Experimental Therapeutics (CGET) conducts translational preclinical and clinical studies related to the pathophysiology and treatment of alcohol use disorder. Our human clinical studies use cutting edge functional imaging, genetic, epigenetic, and pharmacogenetic approaches to investigate neurobiological mechanisms of alcohol use disorder and to explore novel targets for personalized treatments. Our clinical studies include early phase 1/phase 2 proof-of-concept studies of experimental therapeutics guided by molecular biomarker profiling. Translational projects focus on identifying molecular mechanisms involved in addictions, utilizing a wide array of methods including human population genetics, genome wide genotyping approaches, next-generation DNA and RNA sequencing and epigenetic/proteomic profiling.